婦科藥物市場 - 全球產業規模、佔有率、趨勢、機會和預測，按治療、按適應症、按配銷通路、按地區和競爭細分，2019-2029F

2023 年全球婦科藥物市場估值為57.4 億美元，預計在預測期內將出現令人印象深刻的成長，到2029 年複合年成長率為7.18%。包括婦科疾病盛行率的上升子宮肌瘤、子宮內膜異位症和多囊性卵巢症候群（PCOS）等疾病。意識的提高和診斷技術的改進導致更早發現和治療，從而增加了對婦科藥物的需求。藥物研究和開發的進步正在產生更有效、更有針對性的治療方法，改善患者的治療效果。女性人口老化和更年期疾病發病率的增加促進了市場的成長。發展中地區醫療保健基礎設施和服務的擴展進一步支持了市場發展。生活方式的改變和壓力會導致婦科問題，因此需要醫療干預。監管部門的批准和新藥的推出也在市場擴張中發揮重要作用。總的來說，這些因素正在推動全球婦科藥物市場向前發展，反映出人們對女性健康和福祉的日益關注。

市場概況
預測期	2025-2029
2023 年市場規模	57.4億美元
2029 年市場規模	65.2億美元
2024-2029 年複合年成長率	7.18%
成長最快的細分市場	荷爾蒙療法
最大的市場	北美洲

主要市場促進因素

婦科疾病的盛行率

藥物研究的進展

女性人口老化

提高認知和教育

主要市場挑戰

研發成本高

取得和負擔能力問題

主要市場趨勢

藥物傳輸技術的進步

改善醫療基礎設施

細分市場洞察

治療見解

適應症見解

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球婦科藥物市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依治療方法（非荷爾蒙療法和荷爾蒙療法）
  • 依適應症分類（避孕、婦科感染、女性不孕症、停經後疾病、多囊性卵巢症候群、骨質疏鬆症、婦科癌症、子宮內膜異位症、其他）
  • 依配銷通路（零售藥局、醫院藥局、網路藥局）
  • 按地區
  • 按公司分類 (2023)
• 市場地圖

第 6 章：北美婦科藥物市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 透過治療學
  • 按指示
  • 按配銷通路
  • 按國家/地區
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第 7 章：歐洲婦科藥物市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 透過治療學
  • 按指示
  • 按配銷通路
  • 按國家/地區
• 歐洲：國家分析
  • 德國
  • 英國
  • 義大利
  • 法國
  • 西班牙

第 8 章：亞太婦科藥物市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 透過治療學
  • 按指示
  • 按配銷通路
  • 按國家/地區
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第 9 章：南美婦科藥物市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 透過治療學
  • 按指示
  • 按配銷通路
  • 按國家/地區
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東和非洲婦科藥物市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 透過治療學
  • 按指示
  • 按配銷通路
  • 按國家/地區
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 促進要素
• 挑戰

第 12 章：市場趨勢與發展

• 併購（如有）
• 產品發布（如有）
• 最近的發展

第 13 章：波特的五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 客戶的力量
• 替代產品的威脅

第14章：競爭格局

• Amgen Inc.
• Novartis AG
• Bayer AG
• Merck & Co., Inc.
• Eli Lilly and Company
• Pfizer Inc.
• Abbott Laboratories Inc.
• AbbVie Inc.
• GlaxoSmithKline Plc
• Lupin Limited

第 15 章：策略建議

第16章調查會社について,免責事項

Global Gynecology Drugs Market was valued at USD 5.74 Billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.18% through 2029. The global gynecology drugs market is driven by several key factors, including the rising prevalence of gynecological disorders such as uterine fibroids, endometriosis, and polycystic ovary syndrome (PCOS). Increased awareness and improved diagnostic techniques are leading to earlier detection and treatment, thereby boosting demand for gynecological medications. Advances in pharmaceutical research and development are yielding more effective and targeted therapies, enhancing patient outcomes. The aging female population and growing incidence of menopausal disorders contribute to market growth. The expansion of healthcare infrastructure and access in developing regions further supports market development. Lifestyle changes and stress, contributing to gynecological issues, necessitate medical intervention. Regulatory approvals and the introduction of novel drugs also play a significant role in market expansion. Collectively, these factors are propelling the global gynecology drugs market forward, reflecting an increased focus on women's health and well-being.

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 5.74 Billion
Market Size 2029	USD 6.52 Billion
CAGR 2024-2029	7.18%
Fastest Growing Segment	Hormonal Therapy
Largest Market	North America

Key Market Drivers

Prevalence of Gynecological Disorders

Gynecological disorders, including uterine fibroids, endometriosis, PCOS, and various cancers, are increasingly common worldwide, driving the demand for effective pharmaceutical interventions. Uterine fibroids, for instance, affect a significant percentage of women, often leading to symptoms such as heavy menstrual bleeding, pelvic pain, and reproductive issues, which necessitate medical treatment. The burden of endometriosis, characterized by the presence of endometrial tissue outside the uterus, causes severe pain and infertility, requiring long-term management through medications like gonadotropin-releasing hormone (GnRH) agonists and nonsteroidal anti-inflammatory drugs (NSAIDs).

According to a cross-sectional study conducted in two rural Indian villages examined the prevalence of gynaecological among women in the population. Among the 650 women included in the study, 55% reported experiencing gynaecological complaints, while 45% were symptom-free. Notably, 92% of all women were diagnosed with one or more gynaecological, with an average of 3.6 diseases per woman. Genital tract infections accounted for half of this morbidity. Merely 8% of the women had previously undergone gynaecological examination and treatment. The study identified a correlation between the presence of gynaecological diseases and the use of female contraception methods, although this association explained only a small portion of the overall morbidity. These findings underscore the importance of integrating gynaecological care into primary health services in rural regions of developing countries. Enhanced diagnostic capabilities in emerging marktes, including advanced imaging techniques and molecular diagnostics, have led to earlier and more accurate identification of gynecological disorders, further driving the demand for appropriate medical treatments. Increased awareness and screening programs contribute to higher detection rates, necessitating a robust pharmaceutical response to manage and treat these conditions effectively.

Advancements in Pharmaceutical Research

Innovations in pharmaceutical research and development have significantly advanced the treatment landscape for gynecological conditions. Novel drug formulations, including hormone therapies, targeted biologics, and non-hormonal medications, are at the forefront of these developments, offering more precise and effective symptom management. Hormone therapies, such as selective estrogen receptor modulators (SERMs) and progestins, play a crucial role in treating conditions like endometriosis and menopausal symptoms, providing tailored approaches to hormone regulation. Targeted biologics, designed to interfere with specific molecular pathways, offer promising treatments for gynecological cancers and severe conditions like uterine fibroids, enhancing efficacy while minimizing side effects. Non-hormonal medications, including NSAIDs and innovative pain management drugs, address the need for alternative treatments for patients who cannot or prefer not to use hormonal options.

Continuous investments in R&D are essential for addressing unmet medical needs, such as more effective treatments for polycystic ovary syndrome (PCOS) and better management of gynecological cancers. These investments also focus on improving the safety profiles of existing drugs, reducing adverse effects, and increasing patient adherence. Overall, advancements in pharmaceutical research and development are crucial for enhancing the efficacy and safety of gynecology drugs, leading to better health outcomes for women worldwide.

Aging Female Population

As the global population ages, the number of women experiencing menopause and related disorders such as osteoporosis and hormone imbalances increases markedly. According to a study published in PubMed, by the year 2025, the global population of elderly women is projected to reach 604 million, with 70% of them residing in developing nations, and within this demographic, 70% will be located in rural areas. A critical matter necessitating both research and policy focus is the interconnectedness of women's economic, health, and social issues, which escalate with advancing age. Postmenopausal women are at a higher risk for developing osteoporosis due to decreased estrogen levels, leading to weakened bones and increased fracture risk. This demographic shift drives substantial demand for hormone replacement therapies (HRT) and other medications aimed at managing menopausal symptoms and preventing osteoporosis. HRT, which involves the administration of estrogen and sometimes progesterone, is widely used to alleviate menopausal symptoms and protect bone health. Non-hormonal treatments and lifestyle modifications are becoming more popular as women seek personalized approaches to managing their health. This aging demographic trend significantly impacts the gynecology drugs market, as older women are more likely to require medical interventions for a variety of gynecological conditions, including the management of menopausal symptoms and prevention of related health issues. Consequently, pharmaceutical companies are increasingly focusing on developing and marketing therapies tailored to this growing segment of the population.

Increased Awareness and Education

Growing awareness about women's health issues and the importance of early detection and treatment of gynecological disorders have significantly increased healthcare-seeking behavior. Educational campaigns by health organizations and pharmaceutical companies have played a crucial role in this heightened awareness. These initiatives emphasize the importance of regular gynecological check-ups, early diagnosis, and timely intervention in managing conditions such as uterine fibroids, endometriosis, and cervical cancer. Public health campaigns, social media outreach, and community-based programs disseminate vital information about symptoms, risk factors, and available treatments, empowering women to take proactive steps in managing their health. As a result, better-informed patients are more likely to recognize early signs of gynecological issues and seek medical advice and treatment promptly. This shift in behavior leads to increased demand for gynecology drugs, as more women pursue both preventive and therapeutic measures. Pharmaceutical companies also contribute by providing educational resources and supporting awareness initiatives, further driving market growth. The combined efforts of healthcare providers, non-profit organizations, and the pharmaceutical industry create a well-informed patient population that actively participates in managing their gynecological health, thereby boosting the demand for related medications and treatments.

Key Market Challenges

High Research and Development Costs

The high costs associated with research and development (R&D) in the pharmaceutical industry pose a substantial challenge to the global gynecology drugs market. Developing a new drug involves a lengthy and expensive process that includes initial discovery, preclinical testing, and multiple phases of clinical trials. Each phase is associated with significant financial investment, with no guarantee of success. It is estimated that bringing a new drug to market can cost upwards of $2 billion and take over a decade.

Gynecological conditions often require complex, targeted treatments, increasing the complexity and cost of R&D. For example, hormonal therapies and biologics used to treat conditions like endometriosis or ovarian cancer demand sophisticated research and advanced technologies. The high failure rate in clinical trials adds to the financial burden, as only a small fraction of investigational drugs eventually receives regulatory approval. The necessity for continuous innovation to address unmet medical needs and improve existing therapies compounds the financial pressure. Companies must invest in cutting-edge technologies and maintain extensive research facilities and highly skilled personnel. These high costs can be a deterrent, particularly for smaller companies or those operating in developing markets with limited financial resources.

Access and Affordability Issues

Access and affordability of gynecology drugs remain critical challenges, especially in low- and middle-income countries (LMICs). Many women in these regions lack access to basic healthcare services, including essential medications for gynecological conditions. Economic constraints, coupled with inadequate healthcare infrastructure, limit the availability and affordability of necessary treatments. High out-of-pocket costs for medications can be prohibitive, leading to untreated or poorly managed conditions.

Insurance coverage for gynecology drugs varies widely across different countries and regions. In some areas, comprehensive coverage may be lacking, resulting in high costs for patients. Even in developed countries, insurance policies may not cover all available treatments, particularly newer or more expensive drugs. This disparity in coverage creates inequality in access to care, affecting patient outcomes. Pharmaceutical companies also face pricing pressures from governments and health systems seeking to manage healthcare costs. These pressures can limit the profitability of new drugs, discouraging investment in the development of innovative treatments for gynecological conditions. Patent expirations and the subsequent introduction of generic drugs can impact the market dynamics, often leading to reduced prices and margins for original manufacturers.

Key Market Trends

Technological Advancements in Drug Delivery

Technological advancements in drug delivery systems, such as transdermal patches, long-acting injectables, and intrauterine devices, enhance the efficacy and convenience of gynecology drugs. Conventional treatments for gynaecological conditions such as endometriosis, polycystic ovary syndrome (PCOS), and others often involve administering medications systemically, which may result in potential side effects and reduced efficacy. However, recent advancements have focused on delivering therapies directly to the affected areas, aiming to optimize treatment outcomes while mitigating adverse effects. Nanoparticles, characterized by their small size and unique properties, can be engineered to transport drugs precisely to the target site. For instance, researchers are investigating the utilization of nanocarriers to deliver anti-inflammatory drugs for treating endometriosis. By specifically targeting the inflamed tissues, these nanocarriers increase the drug concentration at the site of action, potentially enhancing therapeutic effectiveness and minimizing side effects associated with systemic drug administration. These advanced delivery methods improve patient compliance and treatment outcomes. Innovations in drug delivery technology continue to transform the gynecology drugs market, offering new avenues for effective and user-friendly treatments.

Improved Healthcare Infrastructure

The expansion and improvement of healthcare infrastructure, particularly in developing regions, have significantly enhanced access to gynecological care for a larger population. Government initiatives and substantial investments in healthcare facilities have been pivotal in this transformation. These efforts include building new hospitals, upgrading existing clinics, and equipping them with modern medical technologies necessary for effective gynecological treatment. Training and deploying more healthcare professionals, such as gynecologists, nurses, and midwives, ensure that women receive high-quality care. Programs aimed at educating and empowering women about their health rights and the importance of regular medical check-ups have also increased the demand for gynecological services.

As a result, improved access to comprehensive healthcare services has led to a rise in the diagnosis and treatment of various gynecological conditions. This translates into higher prescription rates for gynecology drugs, as more women seek medical attention for issues such as menstrual disorders, hormonal imbalances, and reproductive health concerns. The improved healthcare infrastructure not only facilitates better patient outcomes but also supports ongoing public health efforts to address and manage women's health issues more effectively across developing regions. This holistic enhancement of healthcare systems is a crucial driver of the global gynecology drugs market, promoting greater health equity and access.

Segmental Insights

Therapeutics Insights

Based on the Therapeutics, hormonal therapy currently dominates the global gynecology drugs market compared to non-hormonal therapy. Hormonal therapies are extensively utilized for managing a broad range of gynecological conditions, such as menopausal symptoms, polycystic ovary syndrome (PCOS), endometriosis, and hormonal imbalances. These therapies often involve the use of estrogen, progesterone, or a combination of both, which are highly effective in alleviating symptoms like hot flashes, irregular menstrual cycles, and severe menstrual pain. Hormonal contraceptives, including pills, patches, and intrauterine devices (IUDs), also form a significant part of this segment, providing not only birth control but also therapeutic benefits for conditions like heavy menstrual bleeding and acne associated with hormonal fluctuations.

The dominance of hormonal therapy can be attributed to its established efficacy, widespread clinical use, and extensive research backing its applications. For instance, hormone replacement therapy (HRT) remains a gold standard for managing menopausal symptoms and preventing osteoporosis in postmenopausal women. Advancements in hormonal delivery methods, such as long acting injectables and transdermal systems, have enhanced patient compliance and convenience, further solidifying the preference for hormonal treatments.

Indication Insights

Based on the Indication segment, the contraception segment is currently dominating. This dominance is driven by several factors, including the high global demand for effective birth control methods, the broad range of available contraceptive options, and substantial investments in research and development by pharmaceutical companies. Contraceptive drugs, including oral contraceptive pills, patches, injections, and intrauterine devices (IUDs), are widely used across the globe due to their effectiveness, convenience, and accessibility.

The global focus on family planning and reproductive health has significantly boosted the use of contraceptive methods. Government initiatives and international organizations, such as the World Health Organization (WHO) and the United Nations (UN), actively promote family planning programs, aiming to improve maternal health, reduce unintended pregnancies, and empower women to make informed choices about their reproductive health. These initiatives have led to increased awareness and adoption of contraceptive methods, further propelling market growth. Technological advancements and continuous innovation in contraceptive products also contribute to this segment's dominance. For example, the development of long-acting reversible contraceptives (LARCs), such as hormonal IUDs and subdermal implants, has provided women with more reliable and convenient options. These methods are highly effective, require minimal maintenance, and offer long-term protection, making them attractive choices for many women. Advancements in non-hormonal contraceptive methods, such as the introduction of new barrier methods and spermicides, are expanding the market.

Regional Insights

North America is dominating the global gynecology drugs market. Several factors contribute to the region's prominent position in this market segment. North America boasts advanced healthcare infrastructure and high healthcare expenditure, providing widespread access to gynecological care and medications. The region's robust pharmaceutical industry is characterized by significant research and development (R&D) investments, fostering innovation in gynecology drugs. North America has a large and aging female population, driving demand for gynecological medications to manage menopausal symptoms, hormone-related disorders, and gynecological cancers. The prevalence of lifestyle-related conditions such as polycystic ovary syndrome (PCOS) and endometriosis further fuels the demand for pharmaceutical interventions.

Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and Health Canada maintain stringent standards for drug approval, ensuring the safety and efficacy of gynecology drugs in the market. While these regulations can pose challenges for market entry, they also inspire confidence among healthcare providers and patients regarding the quality of available medications. North America benefits from a strong network of healthcare providers, including gynecologists, obstetricians, and primary care physicians, who play a pivotal role in prescribing and administering gynecology drugs. Increasing awareness about women's health issues and preventive care initiatives contribute to the region's dominance in the gynecology drugs market.

Key Market Players

Amgen Inc.

Novartis AG

Bayer AG

Merck & Co., Inc.

Eli Lilly and Company

Pfizer Inc.

Abbott Laboratories Inc.

AbbVie Inc.

GlaxoSmithKline Plc

Lupin Limited

Report Scope:

In this report, the Global Gynecology Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gynecology Drugs Market, By Therapeutics:

Non-Hormonal Therapy Hormonal Therapy

Gynecology Drugs Market, By Indication:

Contraception Gynecology Infections Female Infertility Postmenopausal disorders Polycystic Ovary Syndrome Osteoporosis Gynecology Cancer Endometriosis Others

Gynecology Drugs Market, By Distribution Channel:

Retail Pharmacies Hospital Pharmacies Online Pharmacies

Gynecology Drugs Market, By Region:

North America
• United States
• Canada
• Mexico
Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
South America
• Brazil
• Argentina
• Colombia
Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gynecology Drugs Market.

Available Customizations:

Global Gynecology Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

• 4.1. Clinical Trial Analysis
• 4.2. Ongoing Clinical Trials
• 4.3. Completed Clinical Trials
• 4.4. Terminated Clinical Trials
• 4.5. Breakdown of Pipeline, By Development Phase
• 4.6. Breakdown of Pipeline, By Status
• 4.7. Breakdown of Pipeline, By Therapeutic Area
• 4.8. Breakdown of Pipeline, By Region
• 4.9. Clinical Trials Heat Map

5. Global Gynecology Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapeutics (Non-Hormonal Therapy and Hormonal Therapy)
  • 5.2.2. By Indication (Contraception, Gynecology Infections, Female Infertility, Postmenopausal disorders, Polycystic Ovary Syndrome, Osteoporosis, Gynecology Cancer, Endometriosis, Others)
  • 5.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2023)
• 5.3. Market Map

6. North America Gynecology Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapeutics
  • 6.2.2. By Indication
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Gynecology Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapeutics
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Gynecology Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapeutics
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Gynecology Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapeutics
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Distribution Channel

7. Europe Gynecology Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapeutics
  • 7.2.2. By Indication
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Gynecology Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapeutics
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. United Kingdom Gynecology Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapeutics
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Italy Gynecology Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapeutics
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. France Gynecology Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapeutics
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Gynecology Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapeutics
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Gynecology Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapeutics
  • 8.2.2. By Indication
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Gynecology Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapeutics
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Gynecology Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapeutics
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Gynecology Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapeutics
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Gynecology Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapeutics
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Gynecology Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapeutics
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Distribution Channel

9. South America Gynecology Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapeutics
  • 9.2.2. By Indication
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Gynecology Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapeutics
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Gynecology Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapeutics
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Gynecology Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapeutics
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Gynecology Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapeutics
  • 10.2.2. By Indication
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Gynecology Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapeutics
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Gynecology Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapeutics
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Gynecology Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapeutics
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Amgen Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Novartis AG
• 14.3. Bayer AG
• 14.4. Merck & Co., Inc.
• 14.5. Eli Lilly and Company
• 14.6. Pfizer Inc.
• 14.7. Abbott Laboratories Inc.
• 14.8. AbbVie Inc.
• 14.9. GlaxoSmithKline Plc
• 14.10. Lupin Limited

15. Strategic Recommendations

16. About Us & Disclaimer